Spots Global Cancer Trial Database for Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

Official Title: Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon

Study ID: NCT00378521

Conditions

Raynaud's Disease

Raynaud's Disease Secondary to Scleroderma

Raynaud's Disease Secondary to Autoimmune Disease

Interventions

MQX-503

Study Description

Brief Summary: The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.

Detailed Description: The Purpose of this clinical study is to determine, in a controlled fashion, the response to two dosage strengths of a topical gel formulation of Nitroglycerin, MQX-503, in the determination of changes in finger blood flow and skin temperature in the fingers of patients with moderate to severe primary Raynaud's phenomenon and with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma. The dosage strength response in the treatment of the symptoms (pain, tingling, numbness) will also be monitored.